Effects of Sevelamer and Calcium-Based Phosphate Binders on Mortality in Hemodialysis Patients: Results of a Randomized Clinical Trial

Journal of Renal Nutrition

Volumn 18, Issue 1, 2008, Pages 91-98

  Suki, Wadi N ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; CALCIUM DERIVATIVE; CHELATING AGENT; PHOSPHATE BINDING PROTEIN; POLYAMINE; SEVELAMER;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ADULT; AGED; CALCIUM CARBONATE; CALCIUM COMPOUNDS; CAUSE OF DEATH; CHELATING AGENTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT SELECTION; PHOSPHATE-BINDING PROTEINS; POLYAMINES; RENAL DIALYSIS;

EID: 37049000335     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.10.019     Document Type: Article

References (21)

1. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
2. Guerin A.P., London G.M., Marchais S.J., and Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 (2000) 1014-1021
3. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., and Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
4. Blacher J., Guerin A.P., Pannier B., Marchais S.J., and London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 (2001) 938-942
5. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., and London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999) 2434-2439
6. Braun J., Oldendorf M., Moshage W., Heidler R., Zeitler E., and Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27 (1996) 394-401
7. Chertow G.M., Burke S.K., Raggi P., and Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 (2002) 245-252
8. Chertow G.M., Raggi P., McCarthy J.T., et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23 (2003) 307-314
9. Asmus H.G., Braun J., Krause R., et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20 (2005) 1653-1661
10. Braun J., Asmus H.G., Holzer H., et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62 (2004) 104-115
11. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis 27 (1974) 365-375
12. Fleming T.R., Harrington D.P., and O'Brien P.C. Designs for group sequential tests. Control Clin Trials 5 (1984) 348-361
13. Hebert P.L., Geiss L.S., Tierney E.F., Engelgau M.M., Yawn B.P., and McBean A.M. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14 (1999) 270-277
14. Kimura K., Saika Y., Otani H., Fujii R., Mune M., and Yukawa S. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int 71 Suppl (1999) S238-S241
15. Raggi P., Boulay A., Chasan-Taber S., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 39 (2002) 695-701
16. Young E.W., Albert J.M., Satayathum S., et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 (2005) 1179-1187
17. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., and Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 (2003) 446-456
18. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16 (2005) 1115-1125
19. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002) 2010-2019
20. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
21. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248